Anti-Fibrinolytic Drugs - Canada

Canada

In Canada, the revenue in the Anti-Fibrinolytic Drugs market is projected to reach €296.90m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 4.97%, resulting in a market volume of €378.40m by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with a projected revenue of €9,141.00m in 2024.
Canada's pharmaceutical industry is witnessing a growing demand for anti-fibrinolytic drugs due to an increasing prevalence of cardiovascular diseases in the country.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The market for Anti-Fibrinolytic Drugs in Canada has been growing steadily in recent years.

Customer preferences: Anti-Fibrinolytic Drugs are used to prevent excessive bleeding during surgeries or in patients with certain medical conditions. As such, the primary customers for these drugs are hospitals and healthcare providers. In Canada, there has been a growing demand for these drugs due to an aging population and an increase in the number of surgeries being performed.

Trends in the market: One of the key trends in the Anti-Fibrinolytic Drugs market in Canada is the growing use of these drugs in cardiac surgeries. With an increase in the number of heart surgeries being performed in the country, there has been a corresponding increase in the demand for Anti-Fibrinolytic Drugs. Another trend in the market is the growing preference for topical administration of these drugs. This method of administration is less invasive and has fewer side effects compared to intravenous administration.

Local special circumstances: Canada has a publicly-funded healthcare system, which means that the government plays a significant role in the procurement and distribution of Anti-Fibrinolytic Drugs. This has led to a more centralized market, with a limited number of suppliers and distributors. Additionally, there are strict regulations in place governing the use of these drugs, which can affect their availability and pricing.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Canada can be attributed to a number of underlying macroeconomic factors. These include an aging population, which has led to an increase in the number of surgeries being performed, as well as a growing demand for healthcare services. Additionally, the country's strong economy and stable political environment have made it an attractive market for pharmaceutical companies looking to expand their operations.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.